CBP-4888
sFlt1-mediated Preterm Preeclampsia
Clinical Development (Phase not specified)Active, Orphan Drug Designation from EMA (April 2025)
Key Facts
Indication
sFlt1-mediated Preterm Preeclampsia
Phase
Clinical Development (Phase not specified)
Status
Active, Orphan Drug Designation from EMA (April 2025)
Company
About Comanche Biopharma
Comanche Biopharma is a private biotechnology company focused on developing the first therapy targeting a root cause of preeclampsia, a serious hypertensive disorder of pregnancy. The company's lead candidate, CBP-4888, is an siRNA medicine designed to reduce elevated soluble fms-like tyrosine kinase-1 (sFlt1) levels, a key driver of preterm preeclampsia. With recent EMA Orphan Drug Designation and key leadership appointments, Comanche is advancing its clinical development program to address a significant unmet medical need in maternal-fetal health. The company emphasizes ethical representation in clinical trials and global accessibility for its potential therapies.
View full company profile